FDA On Personalized Medicine: Don’t Skimp On Diagnostic Quality Development
This article was originally published in The Gray Sheet
Executive Summary
A CDRH representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.
You may also be interested in...
The Clinical Laboratory Of The Future: Can Technology Fill The Gaps?
Clinical laboratories in the US and Europe are facing pressure from all sides as budget cuts and staffing shortages compete with a growing demand for ever-more-sophisticated lab tests to serve an aging population. As a result, lab directors are seeking innovative ways to improve efficiency and do more with less, and those goals are driving innovation in technology-based solutions such as laboratory automation and informatics. These solutions are increasingly becoming integrated into the total laboratory process – encompassing not only sample analysis, but also up- and downstream workflows – paving the way for the fully integrated, automated lab of the future.
Views Differ On How Lab-Developed Tests Fit In FDA Companion Dx Guidance
Laboratory-developed tests are not explicitly mentioned in FDA’s 12-page draft guidance on companion diagnostics issued this summer, but the issue attracted significant attention in written comments in response to the document.
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.